News
-
Boehringer Ingelheim has announced the approval of Striverdi Respimat olodaterol SMI for the treatment of COPD in the United Kingdom, Denmark and Iceland, noting that additional approvals in EU countries “will follow in due course.”… Read more . . .
-
Discovery Laboratories has submitted an investigational new drug (IND) application for its Aerosurf aerosolized KL4 surfactant for the treatment of respiratory distress syndrome (RDS) in premature infants, the company has announced. Assuming the FDA review… Read more . . .
-
Cystic Fibrosis Foundation Therapeutics (CFFT) has awarded Savara Pharmaceuticals $1.7 million for further development of AeroVanc inhaled vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis patients. CFFT is a… Read more . . .
-
Insmed has announced that it anticipates discussions with the EMA by the end of 2013 regarding Arikace inhaled liposomal amikacin for the treatment of nontuberculous mycobacterial (NTM) lung disease and that it has already initiated… Read more . . .
-
Under a new joint venture, Harmony Asset will pay development costs for Dance Biopharm’s Adagio inhaled insulin in Asian countries, including Korea, India, Indonesia and Australia, Dance has announced. The agreement excludes Japan. Harmony will… Read more . . .
-
Inhalation testing automation specialist Astech Projects has announced the launch of a new website at www.astechprojects.com. The new site allows for easier access to information about the company’s business units, including drug delivery automation. The… Read more . . .
-
UK-based CDMO Aesica has announced that it will expand its services related to inhalation product development and manufacturing at its Nottingham site and that it plans to open a new inhalation technical center in late… Read more . . .
-
According to MannKind Corporation, the company resubmitted its new drug application for Afrezza insulin inhalation powder for the treatment of type 1 and type 2 diabetes to the FDA on October 13, 2013. The resubmitted… Read more . . .
-
Teva has announced that the US FDA has approved its tobramycin inhalation solution, a generic equivalent to Novartis’s TOBI inhalation solution for the treatment of P. aeruginosa infections in cystic fibrosis patients. According to Teva,… Read more . . .
-
Nephron Pharmaceuticals has announced a voluntary recall of ten lots of albuterol inhalation solution “as a precautionary measure, due to results from . . . internal monitoring processes.” The company says that it has not… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA